Comprehensive Stock Comparison

Compare Celcuity Inc. (CELC) vs Revolution Medicines, Inc. (RVMD) Stock

Analyze side-by-side fundamentals, valuation, growth, and profitability to decide which stock is the better buy.

Tickers 2 / 10100+ Metrics

Selected Stocks

Add up to 10 tickers. Use presets or search to get started.

2 / 10
Try these comparisons:

Quick Verdict

CategoryWinnerWhy
Stability / SafetyRVMDBeta 0.99 vs CELC's 1.08, lower leverage
DividendsTieNeither pays a meaningful dividend
Momentum (1Y)CELC+10.8% vs RVMD's +150.4%
Efficiency (ROA)CELC-34.2% ROA vs RVMD's -48.0%, ROIC -50.3% vs -54.3%
Bottom line: CELC leads in 2 of 4 categories, making it the stronger pick for investors who prioritize recent price momentum and sentiment and operational efficiency and capital deployment. Revolution Medicines, Inc. is the better choice for capital preservation and lower volatility. As direct sector peers, they can serve as alternatives in the same portfolio allocation.

Who Each Stock Is For

Income & stability

Growth exposure

Long-term compounding (10Y)

Sleep-well-at-night portfolio

Defensive / Recession hedge

Business Model

What each company does and how it makes money

CELCCelcuity Inc.
Healthcare

Celcuity is a clinical-stage biotechnology company developing targeted cancer therapies using its proprietary diagnostic platform. It generates revenue primarily through research collaborations and licensing agreements — notably with Pfizer for its lead drug candidate Gedatolisib — while advancing its pipeline toward commercialization. The company's key advantage is its CELsignia platform, which analyzes living tumor cells to identify specific cancer-driving abnormalities and match patients with targeted treatments.

RVMDRevolution Medicines, Inc.
Healthcare

Revolution Medicines is a clinical-stage biotechnology company developing precision oncology therapies targeting RAS-addicted cancers. It generates revenue primarily through research collaborations and milestone payments — notably from its partnership with Sanofi on SHP2 inhibitors — while advancing its pipeline toward potential future drug sales. The company's competitive advantage lies in its deep expertise in RAS biology and its portfolio of novel inhibitors targeting multiple RAS pathway vulnerabilities that have historically been difficult to drug.

Revenue Breakdown by Segment

How each company's revenue is distributed across its business units

CELCCelcuity Inc.

Segment breakdown not available.

RVMDRevolution Medicines, Inc.
FY 2022
Collaboration Revenue Member
100.0%$35M

Financial Metrics Comparison

Side-by-side fundamentals across 2 stocks. BestLagging

Financial Scorecard

CELC 2RVMD 0
Financial MetricsCELC1/1 metrics
Valuation MetricsTie1/2 metrics
Profitability & EfficiencyTie4/8 metrics
Total ReturnsCELC5/6 metrics
Risk & VolatilityTie1/2 metrics
Analyst Outlook0/0 metrics

CELC leads in 2 of 6 categories — strongest in Financial Metrics and Total Returns. 3 categories are tied.

Financial Metrics (TTM)

CELC and RVMD operate at a comparable scale, with $0 and $0 in trailing revenue.

MetricCELCCelcuity Inc.RVMDRevolution Medici…
RevenueTrailing 12 months$0$0
EBITDAEarnings before interest/tax-$159M-$1.2B
Net IncomeAfter-tax profit-$163M-$1.1B
Free Cash FlowCash after capex-$145M-$914M
Gross MarginGross profit ÷ Revenue
Operating MarginEBIT ÷ Revenue
Net MarginNet income ÷ Revenue
FCF MarginFCF ÷ Revenue
Rev. Growth (YoY)Latest quarter vs prior year
EPS Growth (YoY)Latest quarter vs prior year-31.4%-68.1%
CELC leads this category, winning 1 of 1 comparable metric.

Valuation Metrics

MetricCELCCelcuity Inc.RVMDRevolution Medici…
Market CapShares × price$4.8B$20.1B
Enterprise ValueMkt cap + debt − cash$4.9B$19.9B
Trailing P/EPrice ÷ TTM EPS-39.47x-17.15x
Forward P/EPrice ÷ next-FY EPS est.
PEG RatioP/E ÷ EPS growth rate
EV / EBITDAEnterprise value multiple
Price / SalesMarket cap ÷ Revenue
Price / BookPrice ÷ Book value/share38.12x11.89x
Price / FCFMarket cap ÷ FCF
Evenly matched — CELC and RVMD each lead in 1 of 2 comparable metrics.

Profitability & Efficiency

RVMD delivers a -69.3% return on equity — every $100 of shareholder capital generates $-69 in annual profit, vs $-139 for CELC. RVMD carries lower financial leverage with a 0.10x debt-to-equity ratio, signaling a more conservative balance sheet compared to CELC's 0.85x.

MetricCELCCelcuity Inc.RVMDRevolution Medici…
ROE (TTM)Return on equity-139.1%-69.3%
ROA (TTM)Return on assets-34.2%-48.0%
ROICReturn on invested capital-50.3%-54.3%
ROCEReturn on capital employed-58.0%-53.0%
Piotroski ScoreFundamental quality 0–911
Debt / EquityFinancial leverage0.85x0.10x
Net DebtTotal debt minus cash$75M-$225M
Cash & Equiv.Liquid assets$23M$384M
Total DebtShort + long-term debt$98M$159M
Interest CoverageEBIT ÷ Interest expense-5.02x-49.69x
Evenly matched — CELC and RVMD each lead in 4 of 8 comparable metrics.

Total Returns (with DRIP)

A $10,000 investment in CELC five years ago would be worth $75,942 today (with dividends reinvested), compared to $22,183 for RVMD. Over the past 12 months, CELC leads with a +1084.6% total return vs RVMD's +150.4%. The 3-year compound annual growth rate (CAGR) favors CELC at 111.7% vs RVMD's 56.2% — a key indicator of consistent wealth creation.

MetricCELCCelcuity Inc.RVMDRevolution Medici…
YTD ReturnYear-to-date+11.1%+29.1%
1-Year ReturnPast 12 months+1084.6%+150.4%
3-Year ReturnCumulative with dividends+848.3%+281.2%
5-Year ReturnCumulative with dividends+659.4%+121.8%
10-Year ReturnCumulative with dividends+681.7%+253.0%
CAGR (3Y)Annualised 3-year return+111.7%+56.2%
CELC leads this category, winning 5 of 6 comparable metrics.

Risk & Volatility

RVMD is the less volatile stock with a 0.99 beta — it tends to amplify market swings less than CELC's 1.08 beta. A beta below 1.0 means the stock typically moves less than the S&P 500. CELC currently trades 92.8% from its 52-week high vs RVMD's 82.0% drawdown — a narrower gap to the peak suggests stronger recent price momentum.

MetricCELCCelcuity Inc.RVMDRevolution Medici…
Beta (5Y)Sensitivity to S&P 5001.08x0.99x
52-Week HighHighest price in past year$120.31$124.49
52-Week LowLowest price in past year$7.58$29.17
% of 52W HighCurrent price vs 52-week peak+92.8%+82.0%
RSI (14)Momentum oscillator 0–10059.254.1
Avg Volume (50D)Average daily shares traded610K3.2M
Evenly matched — CELC and RVMD each lead in 1 of 2 comparable metrics.

Analyst Outlook

Wall Street rates CELC as "Buy" and RVMD as "Buy". Consensus price targets imply 19.8% upside for RVMD (target: $122) vs -11.1% for CELC (target: $99).

MetricCELCCelcuity Inc.RVMDRevolution Medici…
Analyst RatingConsensus buy/hold/sellBuyBuy
Price TargetConsensus 12-month target$99.33$122.25
# AnalystsCovering analysts920
Dividend YieldAnnual dividend ÷ price
Dividend StreakConsecutive years of raises
Dividend / ShareAnnual DPS
Buyback YieldShare repurchases ÷ mkt cap0.0%+0.0%
Insufficient data to determine a leader in this category.

Historical Charts

Charts are rendered on first load. Hover for details.

Chart 1Total Return — 5 Years (Rebased to 100)

StockMar 20Feb 26Change
Celcuity Inc. (CELC)1001,349.58+1249.6%
Revolution Medicine… (RVMD)100295.86+195.9%

Celcuity Inc. (CELC) returned +659% over 5 years vs Revolution Medicine… (RVMD)'s +122%. A $10,000 investment in CELC 5 years ago would be worth $75,942 today (including dividends reinvested).

Chart 2Revenue Growth — 10 Years

Stock20162025Change
Celcuity Inc. (CELC)$0.00$0.00
Revolution Medicine… (RVMD)$0.00$0.00

Chart 3EPS Growth — 10 Years

Stock20162025Change
Celcuity Inc. (CELC)-0.49-2.83-477.6%
Revolution Medicine… (RVMD)-0.85-5.95-600.0%

Chart 4Free Cash Flow — 5 Years

2021
$-20M
$-154M
2022
$-36M
$-235M
2023
$-54M
$-358M
2024
$-84M
$-568M
2025
$-914M
Celcuity Inc. (CELC)Revolution Medicine… (RVMD)

Celcuity Inc. generated $-84M FCF in 2024 (-310% vs 2021). Revolution Medicines, Inc. generated $-914M FCF in 2025 (-494% vs 2021).

Loading custom metrics...

CELC vs RVMD: Frequently Asked Questions

7 questions · data-driven answers · updated daily

01

Is CELC or RVMD a better buy right now?

Analysts rate Celcuity Inc. (CELC) a "Buy" — based on 9 analyst ratings — the highest consensus in this comparison. The "better buy" depends entirely on your goals: growth investors should weight revenue trajectory, value investors should weight P/E and PEG, and income investors should weight dividend yield and streak.

02

Which is the better long-term investment — CELC or RVMD?

Over the past 5 years, Celcuity Inc. (CELC) delivered a total return of +659.4%, compared to +121.8% for Revolution Medicines, Inc. (RVMD). A $10,000 investment in CELC five years ago would be worth approximately $76K today (assuming dividends reinvested). Over 10 years, the gap is even starker: CELC returned +681.7% versus RVMD's +253.0%. Past returns do not guarantee future results, and the stock with the higher historical return may already have its best growth priced in.

03

Which is safer — CELC or RVMD?

By beta (market sensitivity over 5 years), Revolution Medicines, Inc. (RVMD) is the lower-risk stock at 0.99β versus Celcuity Inc.'s 1.08β — meaning CELC is approximately 9% more volatile than RVMD relative to the S&P 500. On balance sheet safety, Revolution Medicines, Inc. (RVMD) carries a lower debt/equity ratio of 10% versus 85% for Celcuity Inc. — giving it more financial flexibility in a downturn.

04

Which has better profit margins — CELC or RVMD?

Celcuity Inc. (CELC) is the more profitable company, earning 0.0% net margin versus 0.0% for Revolution Medicines, Inc. — meaning it keeps 0.0% of every revenue dollar as bottom-line profit. Operating margin tells a similar story: CELC leads at 0.0% versus 0.0% for RVMD. At the gross margin level — before operating expenses — CELC leads at 0.0%, reflecting greater pricing power or product mix advantage. Stronger margins indicate durable pricing power, lower cost of revenue, or higher mix of software/services. They are one of the clearest signs of business quality.

05

Which pays a better dividend — CELC or RVMD?

None of the stocks in this comparison currently pay a material dividend. All are effectively zero-yield and should be held for capital appreciation rather than income.

06

Is CELC or RVMD better for a retirement portfolio?

For long-horizon retirement investors, Celcuity Inc. (CELC) is the stronger choice — it scores higher on the combination of lower volatility, dividend reliability, and long-term compounding (low volatility (β 1.08), +681.7% 10Y return). Both have compounded well over 10 years (CELC: +681.7%, RVMD: +253.0%), confirming both are viable long-term holds — but the lower-volatility option typically results in less emotional selling during corrections. Retirement portfolios generally favour predictability over maximum returns. Consult a financial advisor before making allocation decisions.

07

What are the main differences between CELC and RVMD?

Both stocks operate in the Healthcare sector, making this a peer-level intra-sector comparison — the same macro tailwinds and headwinds will affect both. These fundamental differences mean investors should not choose between them on a single metric — the "better stock" depends entirely on which of these characteristics aligns with your investment strategy.

Find Stocks Like These

Explore pre-built screens for each stock's profile, or build a custom screen to find stocks that beat both.

📊
Stocks Like

CELC

Quality Business

  • Sector: Healthcare
  • Market Cap > $100B
Run This Screen
📊
Stocks Like

RVMD

Quality Business

  • Sector: Healthcare
  • Market Cap > $100B
Run This Screen